Introduction
============

Oral delivery is regarded as the most widely used and readily accepted form of drug administration. However, an increasing number of new active pharmaceutical ingredients (APIs) that emerge as a consequence of combinatorial chemistry are poorly water-soluble and lipophilic, which result in poor and erratic absorption in the gastrointestinal tract.[@b1-ijn-10-6425],[@b2-ijn-10-6425] Since the poorly soluble drugs must be dissolved in the gastrointestinal lumen contents before oral absorption, improving the solubility and dissolution rate of poorly soluble APIs is rapidly becoming the leading hurdle for formulation scientists.[@b3-ijn-10-6425],[@b4-ijn-10-6425] Consequently, a variety of strategies have been developed to overcome this obstacle for poorly water-soluble APIs, such as solid dispersions,[@b5-ijn-10-6425],[@b6-ijn-10-6425] nanoemulsion,[@b7-ijn-10-6425] salt formation,[@b8-ijn-10-6425] melt extrusion,[@b9-ijn-10-6425],[@b10-ijn-10-6425] liposomes,[@b11-ijn-10-6425],[@b12-ijn-10-6425] nanostructured lipid carriers,[@b13-ijn-10-6425],[@b14-ijn-10-6425] and micellar systems.[@b15-ijn-10-6425],[@b16-ijn-10-6425]

During the past several years, the use of particle size reduction methods to form stable nanosized particles has been proven to be an effective strategy to address this thorny problem. Nanosuspensions can be defined as liquid dispersion consisting of solid drug nanoparticles, which are stabilized by polymer and/or surfactant.[@b17-ijn-10-6425] According to the Noyes--Whitney equation,[@b18-ijn-10-6425] the reduction of particle size leads to a significant increase in the dissolution rate of the API, which in turn can lead to substantial increases in bioavailability.[@b19-ijn-10-6425],[@b20-ijn-10-6425] The nanoparticles can also adhere to the gastrointestinal mucosa, prolonging the transit time of the drug and consequently bringing a better absorption.

Previous studies have reported the particle size effect of nanosuspensions on drug dissolution and bioavailability.[@b21-ijn-10-6425],[@b22-ijn-10-6425] However, the preparations used were stabilized by different types or ratios of stabilizers, which may not truly reflect the effects of particle size. Until now, research studies of particle size effect using carvedilol particles stabilized with the same kind and content of stabilizers have scarcely been reported.

Carvedilol is an antihypertensive agent with nonselective β-blocking and α~1~-blocking activities. It has been extensively used in the treatment of hypertension, myocardial infarction, and congestive heart failure.[@b23-ijn-10-6425] Carvedilol is sparingly soluble in water with a log*P* of 4.115. Its oral bioavailability in humans as well as in animals is quite low due to extensive first-pass metabolism in liver and the slow dissolution rate in the intestinal tract.[@b24-ijn-10-6425],[@b25-ijn-10-6425] This study aims at developing carvedilol nanosuspensions by antisolvent precipitation--ultrasonication method and investigating the influence of particle size reduction on dissolution rate as well as oral bioavailability of carvedilol.

Materials and methods
=====================

Materials
---------

Carvedilol was purchased from Shandong Qilu Pharmaceutical Co., Ltd. (Jinan, Shandong, People's Republic of China). The commercially available carvedilol tablet (Luode^®^, 10 mg/tablet) was purchased from Beijing Juneng Pharmaceutical Co. Ltd. (Daxing, Beijing, People's Republic of China). α-tocopherol succinate (VES) was obtained from Jiangsu Xixin Vitamin Co., Ltd. (Suqian, Jiangsu, People's Republic of China). Sodium dodecyl sulfate (SDS) was purchased from TianJin Bodi Chemical Holding Co., Ltd. (Hexi, Tianjin, People's Republic of China). Propranolol was purchased from Changzhou Yabang Pharmaceutical Co., Ltd. (Changzhou, Jiangsu, People's Republic of China). Acetone was purchased from Yuwang Chemical Reagent Co. (Shandong, People's Republic of China). All other chemicals and reagents used were of analytical grade or better.

Animals
-------

Wistar rats (male, weighted 200--250 g) and beagle dogs weighing 10--13 kg were provided by the Lab Animal Center of Shenyang Pharmaceutical University (Beijing, People's Republic of China). All the experimental protocols were carried out in accordance with the guidelines for animal experimentation of Shenyang Pharmaceutical University (Shenyang, People's Republic of China) and approved by the animal ethics committee of the institution.

Preparation of the formulations
-------------------------------

The colloidal dispersions were prepared by an antisolvent precipitation method or in combination with an ultrasonication process.

### Microsuspensions

Briefly, carvedilol (296 mg/mL) and VES (195 mg/mL) were completely dissolved in acetone to prepare the organic phase. Then, the organic phase was passed through a 0.45 μm filter (Shanghai Huan'ao Trading Company, Shanghai, People's Republic of China) to remove the possible impurities. At 10°C, 1 mL of the organic solution was instantaneously injected at a stirring rate of 10,000 rpm for 1 minute using a B25 high shear homogenizer (BRT Equipment Technology Co. Ltd., Shanghai, People's Republic of China) into 50 mL of water phase containing 0.47% (w/v) SDS. Then, the micro-suspensions were kept under vacuum at room temperature for 24 hours to remove the acetone.

### Nanosuspensions

The nanoparticles were obtained following the immediately ultrasonication of microsuspensions with an ultrasonic processor (20--25 kHz, Ningbo Scientz Biotechnology Co., Ltd., Zhejiang, People's Republic of China) for 15 minutes (active every 3 seconds for a 3-second duration, 400 W) at 4°C--8°C. To remove the acetone, the nanosuspensions were then kept under vacuum at room temperature for 24 hours.

In order to improve the stability of carvedilol suspensions, the aqueous microsuspensions and nanosuspensions were freeze-dried with cryoprotectant (ie, maltose) at a concentration of 3% w/v. The suspensions were prefrozen in the refrigerator at −75°C for 12 hours and subsequently freeze-dried in a FD-1C-50 freeze-drier (Boyikang Laboratory Instruments Co., Ltd., Beijing, People's Republic of China) at −25°C for 12 hours, followed by a secondary drying phase at 20°C for 4 hours.

Particle size analysis
----------------------

Particle size was determined by laser diffraction using a Coulter LS 230 analyzer (Beckman-Coulter Co., Ltd., Brea, CA, USA) at room temperature. The particle size was volume-weighted and expressed as mean diameter. Each sample was measured three times. The Span value is a statistical parameter used to evaluate the particle size distribution and calculated using the following equation: $$\text{Span} = \left( {D_{90} - D_{10}} \right)/D_{50}$$where D~10~, D~50~, and D~90~ represent 10%, 50%, and 90%, respectively, of the cumulative particle size distribution at the given size.

Scanning electron microscopy
----------------------------

Scanning electron microscopy (SEM, SUPRA 35; Zeiss, Oberkochen, Germany) was employed to evaluate the morphology of carvedilol microsuspensions and nanosuspensions. Prior to observation, the samples were mounted onto metal stubs using a double-sided adhesive tape and sputtered with a thin layer of gold under vacuum.

Solid-state characterization
----------------------------

The solid state of carvedilol in different preparations was evaluated by differential scanning calorimetry (DSC) and powder X-ray diffractometry (PXRD). DSC analysis was performed using a DSC 1 calorimeter (Mettler Toledo, ZH, Schwerzenbach, Switzerland). The samples were scanned at a heating rate of 10°C/min over a temperature range of 50°C--250°C in an aluminum pan and sealed hermetically, using an empty pan as the reference. PXRD was performed using a powder X-ray diffractometer (D/max 2500, Rigaku, Tokyo, Japan) with a copper anode (Cu Kα radiation, *K* =0.15405 nm, 30 kV, 30 mA). The data were recorded over the 2θ range from 3° to 45° at a scan rate of 0.04°.

In vitro dissolution test
-------------------------

Dissolution tests of the preparations (all equivalent to 25 mg of carvedilol) were evaluated in a dissolution apparatus (ZRS-6G, Tianda Tianfa Technology Co., Ltd, Tianjin, People's Republic of China) according to the USP paddle method. The samples were introduced directly into the vessels. The tests were performed at 37°C±0.5°C in 900 mL of dissolution medium with paddle speed set at 100 rpm. Five milliliters samples were drawn, and the same volume of fresh dissolution medium was added at 5, 15, 30, and 60 minutes, respectively. Then, the samples were filtered through a 0.1 μm syringe filter (Shanghai Huan'ao Trading Company, Shanghai, People's Republic of China) immediately before dilution, when necessary. Drug content was determined using a ultraviolet spectrophotometer at 242 nm.

In situ single-pass intestinal perfusion in rats
------------------------------------------------

Briefly, Wistar rats were fasted overnight prior to the experiments, but had free access to water. Each rat was anesthetized with an intraperitoneal injection of urethane (1 g/kg). The anesthetized rats were restrained in a supine position and kept under infrared lamps to maintain body temperature. Following midline incision of the abdomen, approximately 10 cm of the duodenum, jejunum, ileum, and colon were simultaneously exposed, and small incisions were made in both sides of each segments. The segment was rinsed with physiological saline at 37°C, moistened, and covered with absorbent cotton, and then the selected segments were cannulated with plastic tubes, ligated at both sides. The freshly prepared preparations were dispersed in Krebs Ringer's solution (7.8 g NaCl, 0.35 g KCl, 0.37 g CaCl~2~, 1.37 g NaHCO~3~, 0.02 g MgCl~2~, 0.32 g NaH~2~PO~4~, and 1.4 g glucose in 1,000 mL purified water), maintained at 37°C, and then perfused to the selected segments at a flow rate of 0.2 mL/min. Thereafter, samples were collected every 15 minutes, and the experiments lasted for 105 minutes. Microtubes containing the ingoing perfusion solution and the perfusate samples were weighed and recorded. Meanwhile, the length and diameter of the selected segments were determined. Then, all the collected samples and the perfusate solution were diluted with methanol, centrifuged at 13000 rpm for 10 minutes, and stored at −20°C until analysis.

The concentration of carvedilol in these samples was analyzed by high-performance liquid chromatography (HPLC). The HPLC system was composed of a model LC-20A pump (Shimadzu, Kyoto, Japan) and a model SPDM20A programmable photodiode array detector (Shimadzu, Kyoto, Japan) with Diamonsil C18 column (200×4.6 mm, 5 μm) (Dikma, Lake Forest, CA, USA). The mobile phase consisted of methanol, NaH~2~PO~4~/Na~2~HPO~4~ (5.375:1 M ratio) at 33 mM total concentration in water and glacial acetic acid (62:38:0.3, v/v/v). The flow rate was 1.0 mL/minutes, and the effluent was detected at 242 nm.

The perfusion of the free carvedilol solution (carvedilol dissolved in ethanol and then diluted in Krebs Ringer's solution, 10 μg/mL) was performed as control. The effective permeability (*P*~eff~) of drug in the intestinal segments was calculated according to the following equation: $$P_{\text{eff},G} = \frac{- Q\ln\left( {\frac{C_{\text{out}}}{C_{\text{in}}}\frac{Q_{\text{out}}}{Q_{\text{in}}}} \right)}{2\pi rl}$$where *C*~in~ and *C*~out~ are the concentration of the perfusate solution and collected samples, respectively, *Q*~in~ and *Q*~out~ are their respective volumes, *Q* is the flow rate, *r* and *l* are the radius and length of the perfused intestinal segments, respectively.

Pharmacokinetic study
=====================

Preparation of the formulations
-------------------------------

For the convenience of administration in in vivo studies, carvedilol microsuspension and nanosuspension capsules (containing 12.5 mg of carvedilol) were prepared, respectively. Briefly, freeze-dried carvedilol nanosuspensions and microsuspensions were passed through a 60-mesh screen, respectively, and precisely weighed using an electronic balance (Shanghai Minqiao Precise Science Instrument Co., Shanghai, People's Republic of China). The powders were then filled into Coni-Snap^®^ hard gelatin capsule shells (Size 1, CAPSUGEL, Suzhou, People's Republic of China).

In vivo studies in beagle dogs
------------------------------

Six healthy male beagle dogs were divided into three groups comprising two animals in each. A randomized, three-period crossover single-dose study was conducted, and the washout period was 1 week. The dogs were fasted overnight with free access to water. Three types of carvedilol formulations at a dose of 50 mg/body weight were orally administrated to three groups of dogs, ie, carvedilol microsuspension capsules, nanosuspension capsules, and the commercial tablets (the reference preparation). Blood samples (3 mL) were collected before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, and 24 hours after administration. All the blood samples were separated immediately by centrifugation at 5,800 rpm for 10 minutes and stored at −20°C until determination. The concentration of carvedilol in plasma was determined using a validated HPLC assay. The HPLC conditions for carvedilol analysis and plasma sample preparation method conformed to the former research studies.[@b26-ijn-10-6425]

Pharmacokinetic data analysis
-----------------------------

Pharmacokinetic data analysis was carried out using DAS^®^ 2.0 software (Mathematical Pharmacology Professional Committee of China, Shanghai, People's Republic of China). The various pharmacokinetic parameters that were analyzed included peak concentration (*C*~max~), the time to reach *C*~max~ (*T*~max~), and the area under the concentration--time curve (AUC~0−~*~t~*). All results were expressed as mean ± SD values. Analysis of variance test was performed to demonstrate statistical differences using SPSS 12.0 software (SPSS, Chicago, IL, USA). *P*-value less than 0.05 was considered significant.

In vivo irritation test
-----------------------

Wistar rats were used to evaluate the oral tolerance to carvedilol nanosuspensions and the coarse suspensions (prepared by dispersing commercial carvedilol tablets in 0.5% sodium carboxymethylcellulose solution and sonicated for 10 minutes). The rats were randomly divided into three groups comprising three animals in each with free access to water and were fasted 12 hours before euthanasia. Carvedilol coarse suspensions and nanosuspensions, 10 mg/body weight, were orally administered to rats in two groups once a day for 7 days, respectively. The control group only received the same amount of saline. Two hours after the last administration, the rats were euthanized, and the tissue samples (5 mm of small intestine) were fixed with 4% formaldehyde, embedded in paraffin, and made into histological sections for histopathology assessments.

Results and discussion
======================

Particle size and SEM analysis
------------------------------

From the preparation and formulation screening processes previously studied,[@b26-ijn-10-6425] the microsuspensions and nanosuspensions with mean particle size of 4,895 nm and 212 nm were prepared ([Table 1](#t1-ijn-10-6425){ref-type="table"}), respectively. Following lyophilization, the microsuspensions and nanosuspensions could be gently redispersed without obvious change in particle size ([Table 1](#t1-ijn-10-6425){ref-type="table"}). Carvedilol nanosuspensions showed narrow size distribution, whereas the microsuspensions were widely distributed (based on the Span value). These data were corresponding to the information gained from SEM analysis. [Figure 1](#f1-ijn-10-6425){ref-type="fig"} presents the morphologies of raw carvedilol, microsuspensions and nanosuspensions obtained by drying at room temperature. These particle size data and SEM images indicated that particles in the two kind of suspensions were different not only in size, but also in shape, which would influence their dissolution behavior and bioavailability.[@b27-ijn-10-6425] Carvedilol coarse powders had an irregular shape, while the microsuspensions were globular cluster like, and the nanosuspensions exhibited a flaky shape.

Solid-state characterization by DSC and PXRD
--------------------------------------------

To study potential changes in crystalline state of different sized drug particles, DSC and PXRD measurements were performed. As shown in the DSC patterns ([Figure 2](#f2-ijn-10-6425){ref-type="fig"}), pure carvedilol shows a single sharp endothermic melting peak at 116.47°C, indicative of crystalline characteristics of carvedilol. For SDS and VES, sharp endothermic peaks were observed at 193.38°C and 76.91°C due to their crystalline state nature. In the physical mixture, the melting peaks of all components appeared but drifted slightly because of mixing. After incorporation into nanosuspensions and microsuspensions, the characteristic peak of carvedilol disappeared completely, irrespective of the particle size, implying the noncrystalline state of the drug. To further confirm the physical state of carvedilol, PXRD measurement was performed. [Figure 3](#f3-ijn-10-6425){ref-type="fig"} shows the PXRD curves of pure carvedilol, VES, SDS powder, physical mixtures, and the freeze-dried carvedilol microsuspensions and nanosuspensions powder. As shown in [Figure 3](#f3-ijn-10-6425){ref-type="fig"}, pure carvedilol, VES, and SDS showed intense and characteristic diffraction peaks, respectively. However, no trace of the typical crystalline peaks of carvedilol was observed for both nanosuspensions and microsuspensions, indicating the noncrystalline state of carvedilol. The results generated from DSC and PXRD in combination illustrated that carvedilol freeze-dried nanosuspension and microsuspension powders were all in the amorphous form state. And the transition from the crystalline state to the amorphous state probably took place during the antisolvent precipitation step.

In vitro dissolution studies
----------------------------

The dissolution profiles of bulk carvedilol, the commercial tablet, microsuspensions, and nanosuspensions are shown in [Figure 4](#f4-ijn-10-6425){ref-type="fig"}. Buffer medium with pH 1.0 was used to ensure sink condition during the dissolution rate testing. The dissolution rates of the four preparations were 20.63%, 38.16%, 78.90%, and 91.94% in 5 minutes, respectively ([Figure 4A](#f4-ijn-10-6425){ref-type="fig"}). Another medium with pH 6.8 was used to compare the drug dissolution rate at a more physiological pH. The dissolution rates of the four preparations were 8.13%, 23.89%, 69.03%, and 90.15% in 60 minutes, respectively ([Figure 4B](#f4-ijn-10-6425){ref-type="fig"}). The results indicated that the dissolution rate of carvedilol from the preparations followed the Noyes--Whitney equation: $$\frac{dC}{dt} = \frac{AD}{h}\left( {C_{s} - C} \right)$$where d*C*/d*t* is the dissolution rate, *D* is the diffusion coefficient of the solute, *A* is the thickness of the dissolution boundary layer, *S* is the surface area, *C*~s~ is the saturation solubility, and *C* is the bulk concentration.[@b28-ijn-10-6425] It is widely accepted that the improvement in dissolution of drug can be ascribed to the particle size reduction, especially to the nanometer range, providing a significant increase in surface area available to dissolve. According to the Prandtl equation, the diffusion distance *h* decreases for very small particles.[@b29-ijn-10-6425] The reduction in diffusion distance *h* and the simultaneous increase in saturation solubility *C*~s~ can also lead to an increased dissolution velocity of the nanosuspensions. Consequently, dissolution studies of the four preparations clearly showed that particle size reduction is a practical way to improve the dissolution rate of carvedilol.

Absorption of carvedilol in rat intestine
-----------------------------------------

The absorption of free carvedilol, microsuspensions, and nanosuspensions in the rat intestine was performed by in situ single-pass intestine perfusion method. The results indicated that the absorption of carvedilol was changed with the site of the intestine segments ([Figure 5](#f5-ijn-10-6425){ref-type="fig"}). Briefly, *P*~eff~ of carvedilol solution was the highest in the jejunum, and decreased in the duodenum, ileum, and colon, which could attribute to the different physiological characteristics of selected intestinal segments. Compared with carvedilol solution, *P*~eff~ of carvedilol nanosuspensions was remarkably increased by 1.74-, 1.42-, 1.89-, and 1.82-fold in the duodenum, jejunum, ileum, and colon, respectively. For microsuspensions, *P*~eff~ increased by 1.38-, 1.12-, 1.42-, and 1.29-fold in the selected intestinal segments, respectively. The *P*~eff~ of nanosuspensions was significantly higher than that of microsuspensions in all of the intestinal segments (*P*\<0.05). It is well known that the diffusion across the unstirred water layer is a crucial barrier to the absorption of poorly water soluble drugs from the intestinal fluid.[@b30-ijn-10-6425] The reduction of carvedilol particle size could promote its diffusion across the unstirred water layer and access the brush border membrane of enterocytes. Moreover, the nanometer-sized particles of carvedilol nanosuspensions could enable the interfacial interaction with the mucin layer, thereby further enhancing the absorption of carvedilol from the intestinal lumen.[@b21-ijn-10-6425] Meanwhile, SDS used in the nanosuspensions and microsuspensions could improve the intestinal absorption of carvedilol from the intestinal epithelium by the paracellular pathway.[@b31-ijn-10-6425] The presence of SDS and VES in the suspensions could also contribute to the increased saturation solubility of carvedilol, and thus improve the absorption of the drug.

Pharmacokinetic study
---------------------

A pharmacokinetic study was performed in beagle dogs to assess the absorption efficiency of carvedilol suspensions. Following oral administration, there were significant differences in pharmacokinetic profiles among the commercial tablets, the microsuspension and nanosuspension capsules. The plasma concentration--time profiles of carvedilol are presented in [Figure 6](#f6-ijn-10-6425){ref-type="fig"}, and the pharmacokinetic parameters are displayed in [Table 2](#t2-ijn-10-6425){ref-type="table"}. As expected, significant increase in absorption was observed with the nano- and microsuspensions. In contrast with carvedilol coarse suspensions (the commercial tablets), the nanosuspensions and microsuspensions had higher *C*~max~ (2.09- and 1.48-fold), AUC~0−~*~t~* (2.11- and 1.51-fold), and shorter *T*~max~ (0.34- and 0.48-fold) (all *P*\<0.05). Furthermore, enhanced absorption was observed with the nanosuspensions as compared with the microsuspensions. These findings were in accordance with the results from the in vitro dissolution and the in situ single-pass perfusion tests, indicating that the differences in carvedilol absorption are primarily attributed to the dissolution and intestinal absorption behavior of carvedilol with different particle sizes. Meanwhile, the direct uptake of the nanoparticles by mechanisms involving M-cells in Peyer's patches of the gastrointestinal lymphoid tissue, thus avoid the first-pass metabolism effect, which is primarily responsible for the low bioavailability of carvedilol. Furthermore, the rapid absorption could attribute to the increased aqueous solubility and the size effect of carvedilol.

Although the results ([Figure 6](#f6-ijn-10-6425){ref-type="fig"} and [Table 2](#t2-ijn-10-6425){ref-type="table"}) showed that the *C*~max~ and AUC~0−~*~t~* were increased with the reduction of particle size, the increase in these parameters can also give rise to pronounced fluctuations in plasma concentration and the more intensified adverse effects such as arrhythmia, hypotension, and so on. To address this issue, we have developed a novel controlled delivery system of carvedilol nanosuspensions.[@b32-ijn-10-6425] The in vivo test in beagle dogs demonstrated that the novel system could significantly improve the bioavailability of carvedilol and that the plasma concentrations were more stable than that of the marketed tablets. It was a promising strategy in improving the oral bioavailability, minimizing the frequency of drug administration, and lowering the average peak plasma concentration of poorly soluble drugs.

In vivo gastrointestinal irritation test
----------------------------------------

The long-term gastrointestinal irritation of carvedilol nanosuspensions was further studied using Wistar rats to exam the irritation effect after oral administration. [Figure 7](#f7-ijn-10-6425){ref-type="fig"} shows the histopathology of the rat gastric mucosa treated with various formulations to observe their effect on tissue integrity and cell structure. Pathology of the rat gastric mucosa demonstrated that there was hardly any evidence of hemorrhagic mucosal erosions and disruption of intestinal villi. The results indicated that there was a good biocompatibility between the preparations and the rat gastric mucosa.

Conclusion
==========

In this study, carvedilol microsuspensions and nanosuspensions were prepared by antisolvent precipitation method or in combination with an ultrasonication process. The solid form of carvedilol altered from the crystalline state to the amorphous state after incorporation into nanosuspensions or microsuspensions. The dissolution and oral absorption properties of the carvedilol suspensions were obviously particle size-dependent and were dramatically enhanced when the particle size was reduced to the nanometer range. *P*~eff~ of nanosuspensions in all of the intestinal segments was greatly improved in the in situ single-pass perfusion experiment compared with carvedilol microsuspensions and solution. The in vivo study demonstrated that the nanosuspensions and microsuspensions had higher *C*~max~ (2.09- and 1.48-fold), AUC~0−~*~t~* (2.11- and 1.51-fold), and shorter *T*~max~ (0.34- and 0.48-fold) in contrast to carvedilol coarse suspensions. Furthermore, carvedilol nanosuspensions showed good biocompatibility with the rat gastric mucosa in in vivo gastrointestinal irritation test. The overall results indicated that particle size reduction to form nanosized particles was found to be an efficient method for improving the oral bioavailability of carvedilol.
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![SEM micrographs.\
**Notes:** SEM micrographs of (**A**) carvedilol coarse powder, (**B**) microsuspensions, and (**C**) nanosuspensions.\
**Abbreviations:** EHT, extra high tension; SEM, scanning electron microscopy; WD, working distance.](ijn-10-6425Fig1){#f1-ijn-10-6425}

![DSC profiles.\
**Notes:** DSC profiles of freeze-dried nanosuspension powder (**A**), freeze-dried microsuspension powder (**B**), physical mixture (**C**), SDS powder (**D**), VES powder (**E**), and coarse carvedilol powder (**F**).\
**Abbreviations:** DSC, differential scanning calorimetry; SDS, sodium dodecyl sulfate; VES, α-tocopherol succinate.](ijn-10-6425Fig2){#f2-ijn-10-6425}

![PXRD patterns.\
**Notes:** PXRD patterns of freeze-dried nanosuspension powder (**A**), freeze-dried microsuspension powder (**B**), physical mixture (**C**), SDS powder (**D**), VES powder (**E**), and coarse carvedilol powder (**F**).\
**Abbreviations:** PXRD, powder X-ray diffractometry; SDS, sodium dodecyl sulfate; VES, α-tocopherol succinate.](ijn-10-6425Fig3){#f3-ijn-10-6425}

![Dissolution profiles.\
**Notes:** Dissolution profiles of bulk carvedilol, the commercial tablet, microsuspensions, and nanosuspensions: buffer of pH 1.0 (**A**); buffer of pH 6.8 (**B**). Each value represents the mean ± SD (n=3).\
**Abbreviation:** CAR, carvedilol.](ijn-10-6425Fig4){#f4-ijn-10-6425}

![In situ absorption.\
**Notes:** The in situ absorption of microsuspensions and nanosuspensions in rat intestinal segments compared with free carvedilol solution. \*Indicates *P*\<0.05 versus free carvedilol solution.\
**Abbreviation:** *P*~eff~, effective permeability.](ijn-10-6425Fig5){#f5-ijn-10-6425}

![Pharmacokinetics profiles.\
**Notes:** In vivo pharmacokinetics profiles of carvedilol in beagle dogs following oral administration of commercial tablets, and microsuspension and nanosuspension capsules (n=6).\
**Abbreviations:** MS, microsuspension; NS, nanosuspension.](ijn-10-6425Fig6){#f6-ijn-10-6425}

![Morphology of rat jejunum cross section.\
**Notes:** Morphology of rat jejunum cross section after oral administration of physiological saline (**A**), coarse suspensions (**B**), and nanosuspensions (**C**). The magnification of the images is 200×.](ijn-10-6425Fig7){#f7-ijn-10-6425}

###### 

Particle size of carvedilol microsuspensions and nanosuspensions (mean ± SD, n=3)

  Preparation              Size distribution (nm)   Span                     
  ------------------------ ------------------------ ----------- ------------ ------
  Microsuspensions                                                           
   Before lyophilization   816±217                  4,895±189   9,987±536    1.87
   After lyophilization    798±239                  4,954±227   10,871±412   2.03
  Nanosuspensions                                                            
   Before lyophilization   177±7                    212±12      255±15       0.37
   After lyophilization    172±13                   224±9       271±6        0.44

**Note:** D~10~, D~50~, and D~90~ represent represent 10%, 50%, and 90%, respectively, of the cumulative particle size distribution.

###### 

In vivo parameters of carvedilol microsuspensions, nanosuspensions, and the commercial tablets after oral administration (n=6)

  Parameters               Microsuspensions                                               Nanosuspensions                                                                                            Commercial tablets
  ------------------------ -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------
  *C*~max~ (μg/mL)         1,567.52±315.10[a](#tfn3-ijn-10-6425){ref-type="table-fn"}     2,224.58±212.78[a](#tfn3-ijn-10-6425){ref-type="table-fn"},[b](#tfn4-ijn-10-6425){ref-type="table-fn"}     1,062.61±416.26
  *T*~max~ (h)             1.31±0.74[a](#tfn3-ijn-10-6425){ref-type="table-fn"}           0.94±0.12[a](#tfn3-ijn-10-6425){ref-type="table-fn"},[b](#tfn4-ijn-10-6425){ref-type="table-fn"}           2.75±0.71
  AUC~0−~*~t~* (μg·h/mL)   6,815.17±1,179.66[a](#tfn3-ijn-10-6425){ref-type="table-fn"}   9,350.85±2,135.53[a](#tfn3-ijn-10-6425){ref-type="table-fn"},[b](#tfn4-ijn-10-6425){ref-type="table-fn"}   4,498.89±1,655.72
  AUC~0−∞~ (μg·h/mL)       7,142.17±1,241.25[a](#tfn3-ijn-10-6425){ref-type="table-fn"}   9,948.70±2,420.09[a](#tfn3-ijn-10-6425){ref-type="table-fn"},[b](#tfn4-ijn-10-6425){ref-type="table-fn"}   4,657.86±1,727.24

**Notes:** All data presented in the form of mean ± SD.

Statistically significant compared with the commercial tablet (*P*\<0.05).

Statistically significant compared with the microsuspensions (*P*\<0.05).
